Implications of MicroRNAs in Oncolytic Virotherapy

Xavier Bofill-De Ros1,2†, Maria Rovira-Rigau1,2 and Cristina Fillat1,2*

1 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 2 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain

MicroRNAs (miRNAs) are an abundant class of small non-coding RNA molecules (~22 nt) that can negatively regulate gene expression. Deregulation of certain miRNAs is widely recognized as a robust biomarker for many neoplasms, as well as an important player in tumorigenesis and the establishment of tumoral microenvironments. The downregulation of specific miRNAs in tumors has been exploited as a mechanism to provide selectivity to oncolytic viruses or gene-based therapies. miRNA response elements recognizing miRNAs expressed in specific tissues, but downregulated in tumors, have been inserted into the 3′UTR of viral genes to promote the degradation of these viral mRNAs in healthy tissue, but not in tumor cells. Consequently, oncolytic virotherapy-associated toxicities were diminished, while therapeutic activity in tumor cells was preserved. However, viral infections themselves can modulate the miRNome of the host cell, and such miRNA changes under infection impact the normal viral lifecycle. Thus, there is a miRNA-mediated interplay between virus and host cell, affecting both viral and cellular activities. Moreover, the outcome of such interactions may be cell type or condition specific, suggesting that the impact on normal and tumoral cells may differ. Here, we provide an insight into the latest developments in miRNA-based viral engineering for cancer therapy, following the most recent discoveries in miRNA biology. Furthermore, we report on the relevance of miRNAs in virus–host cell interaction, and how such knowledge can be exploited to improve the control of viral activity in tumor cells.

Keywords: oncolytic viruses, microRNA, gene regulation, detargeting, host–virus interaction

INTRODUCTION

MicroRNAs (miRNAs) are small non-coding RNA molecules (~22 nt) that can negatively regulate the expression of large networks of genes (1). Not surprisingly, miRNA dysregulation impacts virtually all cancer-related processes (proliferation, cell death, migration, and cell cycle, among many others). Such dysregulation provides clear hallmark miRNA signatures that can distinguish between normal cells and the tumor cells of many different types of malignancy (1).

In this regard, therapeutic strategies rely either on the reintroduction of the individual miRNAs involved in tumor suppression functions, such as miR-34 (2), or on reducing oncogenic miRNAs with antisense oligonucleotides—“antagomirs” (3). Interestingly, Brown and coworkers exploited the differences in miRNA expression between tissues and proposed a novel mechanism to control transgene expression, based on the differential expression of miR-142 among lineages of hematopoietic cells (4). Selectivity was achieved by the introduction of engineered target sites, or miRNA response elements (MREs). Later, oncolytic virotherapy also incorporated MREs to control the expression of viral or suicide genes. MREs can attenuate oncolytic viruses in non-tumoral tissue
and therefore avoid the undesired toxicity associated with viral tropism when administered systemically or locoregionally (5–8). Posttranscriptional targeting with MREs could be complemented with transcriptional or transductional targeting to enhance the selectivity of oncolytic viruses.

The study of viral miRNAs and host responses has also shown the relevance of miRNAs in the regulation of viral replication. There are, in fact, several examples of how viral infection modulates cellular miRNA, with consequences on both viral activity and host cell functionality.

This review discusses the latest developments with respect to fine-tuning oncolytic viruses, based on the viral engineering of MREs, and looks at the functional consequences of the interplay between miRNAs and viruses.

THE MECHANISM OF ACTION OF miRNAs

Most miRNAs are transcribed from miRNA genes and follow a canonical miRNA biogenesis pathway. miRNAs are transcribed to primary miRNA transcripts (pri-miRNAs) that are processed by the RNase III enzyme Drosha in the nucleus to generate precursor miRNA that are exported by Exportin-5 to the cytoplasm. There they are recognized and cleaved by another RNase III enzyme, Dicer, to give rise to ~22 nt miRNA duplexes. They are then loaded onto the RISC complex, where the Ago proteins will help with the unwinding of the miRNA duplexes to form a functional miRNA-induced silencing complex that will recognize target miRNAs and interfere with their expression. Target miRNA recognition will be based on partial complementarity of miRNA sequences and the 3′ UTR of the miRNAs (9).

miRNAs modulate gene expression through mechanisms of translational inhibition, mostly at the initiation step, and mRNA destabilization as a consequence of mRNA deadenylation and mRNA decay. These mechanisms may occur sequentially, with mRNA destabilization as the dominant effect. In consequence, the repression of miRNAs target genes can be evidenced by depletion of the mRNA content (10, 11).

CONTROLLING VIRAL REPLICATION THROUGH MREs

The selectivity of oncolytic viruses can be determined through the introduction of MREs, preferentially in the 3′ UTR of viral genes (12). Noticeably, MREs can be inserted into virtually any viral mRNA. Comparable efficiencies have been observed with MREs targeting early phase transcription factors or late phase capsid structural proteins. Examples of the elements targeted are ICP4, ICP27, and glycoprotein H in herpes simplex virus (13–15), E1A and L5 (fiber) in adenovirus (15, 16), or M and L in vesicular stomatitis virus (17, 18). Interestingly, targeting early phase proteins reduces toxicity derived from its own expression and that of downstream genes, offering a greater safety margin than when targeting late phase proteins (16). However, the use of MREs to target both genomic and messenger RNA in viral viruses showed efficient repression of miRNAs only. The efficacy of miRNA repression in genomic RNAs is reduced due to secondary structures and scaffold proteins that protect the viral genome (5, 19, 20).

The base pairing of the miRNA and target genes usually displays partial complementarity, restricted to nucleotides 2–7 of the miRNA, and known as the “seed” sequence (21, 22). However, partial complementarity can only mediate translational repression and mRNA decay (10, 23–25). To achieve a fast and robust effect on the control of viral replication, MREs must be designed to trigger direct cleavage in the viral mRNA. Although all human Argonaute proteins (Ago1–4) are capable of promoting a translational repression pathway, only Ago2 has endonucleolytic activity (26, 27). In order to trigger Ago2-mediated direct cleavage, the base-pairing miRNA:MRE between nucleotides 10 and 11 must be complete (23). This mechanism of action exploits the same mechanisms as RNAi silencing (shRNA and siRNA) (28). The factors that can influence the efficacy of the MRE include the expression levels and profiles of Ago proteins between tissues (29) and the modulation of their activity by covalent modification (30, 31).

Elements of the design of MRE that contribute to its efficacy include the number of target sites, the distance between target sites, the sequence composition and local RNA structure surrounding its location in the 3′ UTR (Figure 1). The optimal design for MRE should include a range of target sites, usually from 2 to 8, allowing a dose-dependent response to miRNA concentration (32), and a seed separation of between 13 and 35 nt to avoid steric hindrance (33). Access to target sites can usually be estimated through the secondary structure, with the minimum free energy (mfe) and AU-richness surrounding the site (34–36). Moreover, sites for RNA-binding proteins should be avoided since they may also mask MREs and hamper recognition. Hence MRE engineering might benefit from a computed selection of spacers, to promote optimal separation and secondary structure.

The miRNAs considered as regulators to bind to MREs are selected from those that present abundant expression in normal tissue, but a significantly decreased expression in tumors, such as the ubiquitously expressed miRNA let-7 family (18, 37, 38). Other studies have exploited tissue-specific miRNAs. Some examples of tissue-specific MREs are miR-122 for liver (6, 7), miR-7 for brain (39), miR-148a for pancreas (39, 40), and miR-192 for heart (41). In this regard, miRNA belonging to the same family can be used to increase the efficacy of MRE. The extensive homology presented by miRNA of the same family allows sub-optimal recognition of the MRE (Figure 1). An increased level of complexity in the selection of miRNA candidates arises with the design of MREs for multiple organs detargeting, usually non-tumoral cells surrounding the tumor and tissues with native viral tropism (42). This can be achieved by using miRNAs present in both organs, or by combining multiple miRNAs (40). In this context, the extensive miRNome data in The Cancer Genome Atlas (https://cancergenome.nih.gov/) for 33 types of cancer and normal tissue constitutes an invaluable resource for the selection of candidate miRNAs (43). Of special consideration when seeking to fine-tune oncolytic virus activity is the diversity of cell types in tissue, especially in approaches using locoregional administration. Here, MREs could also provide the desired level of selectivity, for example, miR-375 has been described almost exclusively in the beta and alpha cells present in pancreatic islets (44, 45).
An aspect of MRE design, aside from selectivity, that has yet to be tested for oncolytic viruses, is the incorporation of MREs as miRNA sponges or decoys. In other areas of gene therapy, sponge MREs have been used to reduce the effective amount of miRNA content (46–48). These particular MRE designs are characterized by a bulge that impairs the slicing activity of Ago2, while promoting miRNA degradation by way of trimming and tailoring (49). Sponge MREs could be incorporated into oncolytic viruses to downregulate the miRNAs involved in tumor progression (50), increase viral replication, or attenuate host antiviral response (51).

HOST miRNAs RESPONSE TO VIRAL INFECTION

When a virus infects a cell, a host–virus relationship is established, creating an intricate network of interactions characterized by the massive reprogramming of cellular gene expression. The expression profile of cellular mRNAs and miRNAs is affected during viral infection (52, 53). Changes in the host miRNA profile have been reported after infection with adenoviruses (54–56), influenza viruses (57, 58), HIV-1 (59), Epstein–Barr virus (EBV) (60, 61), human cytomegalovirus (HCMV) (62), human herpes virus 1 (HSV-1) (63), and respiratory syncytial virus (64).

By merely observing miRNA profile change, it is difficult to discern whether miRNA deregulation is the consequence of a host-immune response to the infection or if it is triggered by the virus to favor replication. Comparative studies of the expression profiles of different viral infections and the analysis of miRNA targets can help elucidate the significance of deregulation.

The miRNA profile after adenoviral infection has been studied for adenovirus type 3 in human laryngeal epithelial cells (56), adenovirus type 2 (Ad2) in human primary cells (54), and, more recently, for adenovirus type 5 (Ad5) in prostate cancer cells (55). Ad2 infection studies showed that a correlation between the progression of the infectious cycle and the level of miRNA deregulation could be established. Changes in the profile extend...
from more upregulated, during the early stages of infection, to more downregulated miRNAs at the later phases (54). Massive miRNA downregulation could be the consequence of the expression of the VA (viral associated) RNAs codified by the virus at the later stages of the infection, competing with endogenous miRNA biogenesis (55) (Figure 2A). In fact, the same phenomenon was observed following Ad5 infection (55). Ad2 and Ad5 infection triggered miR-155 upregulation, an effect also observed after VSV (65) and EBV infections (61), suggesting that miR-155 could act as a host antiviral miRNA. It is also known that miR-155 is induced in macrophages, in response to interferon pathway activation (66).

Another miRNA that has been reported to be upregulated in cells infected by several viruses is miR-132. It has been found to overexpress after adenovirus (54, 55), HSV, KSHV, and HCMV infection (67). In contrast to miR-155, miR-132 acts by limiting host antiviral response since it exerts a negative effect on the expression of interferon-stimulated genes. This is a viral strategy which seeks to evade host antiviral response and promote viral replication (67, 68) (Figure 2B).

It is probable that viruses have evolved to induce the downregulation of interference miRNAs and favor the upregulation of miRNAs that can facilitate viral replication (54) (Figure 2B). Several examples illustrate this view. HSV-1 causes a series of changes in the miRNA profile and antagonizes host defenses by inducing miR-23a and miR-649 expression. These miRNAs, respectively, target IRF1 and MALT1 genes, involved in the antiviral signaling pathway (63, 69). In turn, the HSV-1 ICP4 protein induces the expression of miR-101, which limits virus replication to ensure the survival of host cells and therefore support persistent HSV-1 infection (70). In cells infected with Reolysin, a reovirus currently being tested for the treatment of several cancers (71), Nuovo et al. observed a modulation of certain miRNAs, with clear downregulation of let-7d, facilitating

REGULATION of miRNAs IN CANCER WITH IMPLICATIONS FOR VIRAL ACTIVITY

As already mentioned, miRNA signatures can not only distinguish between normal and cancer cells but also between cancer subtypes, and even between the cell types conforming the tumor itself. Studies have shown that lower expression, or even loss of miRNAs, is commonly found in tumor cells (80, 81), where most of them are recognized as tumor suppressors. On the other hand, fewer miRNAs are overexpressed in cancer cells and are considered oncomiRs, since they tend to be involved in tumorigenic processes. Both oncomiRs and tumor suppressor miRNAs contribute to different stages of carcinogenesis (82). On this basis, attempts to modulate miRNA expression are an important area of therapeutic development (83). Since many miRNAs are involved in tumorigenesis, the action of expressing or interfering with a single miRNA may have limited anti-cancer effects. The combination of multiple miRNAs with complementary mechanisms may impact on several signal transduction pathways, leading to an improved outcome. In this respect, multiple long non-coding RNAs have been designed for an adenovirus, aiming to cause it to bind to oncomiRs, instead of otherwise binding to endogenous targets, and thus achieving the interference of multiple miRNAs (84).

Cancer cells are coupled with abnormal signaling pathways and this has consequences for viral replication. For example, adenoviruses use interferon signaling to inhibit lytic virus replication
in normal cells. However, they fail to inhibit it from replicating in cancer cells (85). The loss of interferon defenses in tumor cells is one of the mechanisms involved in the cancer selectivity of reovirus (86). Exploiting interferon deregulation in cancer is also a strategy employed to provide oncoselectivity for complex viruses (87, 88). Alterations to a variety of other pathways in cancer have constituted the principle option when seeking to confer cancer selectivity to viruses, with a view to cancer treatment (89, 90). Thus, although very little is yet known, one could speculate that the dysregulation of miRNAs in cancer may impact viral activity in tumor cells. Although the simplest rationale could claim that the more dysregulated miRNAs would be the first candidates when seeking to influence viral replication, recent observation illustrates that this might not always be the case and, in fact, functional intertrogation would always be required. This is a point that was raised by the studies of Hodzic and coworkers, in which they showed that miR-26b, an abundant miRNA in prostate cancer cells, promoted adenovirus propagation and spread, leading to increased cell death (55). Further studies in this direction will provide a clearer view of the relevance that miRNA dysregulation in tumor cells may have with respect to modulating viral activity. Such a body of knowledge could constitute a novel platform in our quest to optimize oncolytic virotherapy.

CONCLUDING REMARKS

Investigation of miRNAs has strongly impacted the field of oncolytic virotherapy. Many studies have shown their potential in precisely detargeting viral protein expression. The expression of viral protein in normal tissue is an undesired effect. They are highly immunogenic proteins that the body tends to eliminate, and can cause inflammation and cell death. Thus, the incorporation of MREs to regulate viral proteins has been key to improving the safety profile and therapeutic index of oncolytic virotherapy. Fine-tuning the design of the MRE has improved the efficacy of both cleavage and detargeting effects.

On the other hand, our understanding of the importance of the role of miRNAs in viral infections is increasing. Virus–host cell interaction impacts cellular miRNAs and alters their miRNome. Viruses take advantage of host cell miRNAs to promote virus replication, but cells react to viral infections by upregulating antiviral miRNAs. Interestingly, biological responses to the viral infection of cancer cells with abnormal signaling pathways are not the same as they would be with normal cells, and miRNAs would also seem to play a role in this differential response.

Up until now, much progress has been made in the engineering of oncolytic viruses with MREs in the attempt to provide improved selectivity and safety for their use. Future research may concentrate on further understanding the relationship between host miRNAs and viral replication, and how this may differentially impact normal and cancer cells. Such knowledge could prove fundamental and serve as the basis for exploiting newly engineered oncolytic viruses with enhanced antitumor potency.

AUTHOR CONTRIBUTIONS

CF coordinated the study and wrote some parts. XB-DR and MR-R wrote part of the manuscript.

FUNDING

Research in the author's laboratory was supported by grants from the Spanish Ministry of Economía y Competitividad (MINECO) BIO2011-30299-C02-01/02, BIO2014-57716-C2-2-R, and RTC-2015-4189-1 and received partial support from the Generalitat de Catalunya SGR14/248. CIBER de Enfermedades Raras is an initiative of the ISCIII. The CF’s group is partially financed by the Instituto de Saludos Carlos III (IIS10/00014) and co-financed by the Fondo Europeo de Desarrollo Regional (FEDER), and also acknowledges the support of COST Action BM1204 EUpancreas and the Spanish Adenovirus Network (AdenoNet, BIO2015-68990-REDT) and the CERCA Programme/Generalitat de Catalunya. XB-DR was recipient of a FPU fellowship (Ministry of Education) and MR-R of a FPI fellowship (MINECO), Spain. The authors have performed their research work at the Centro de Catalunya, Barcelona, Spain.

REFERENCES

1. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian miRNAs are conserved targets of microRNAs. Genome Res (2009) 19:92–105. doi:10.1101/gr.082701.108
2. Daige CL, Wiggins JF, Priddy L, Bellugar-Davis T, Zhao J, Brown D. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther (2014) 13:2352–60. doi:10.1158/1535-7163.MCT-14-0209
3. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther (2011) 18:1104–10. doi:10.1038/gt.2011.50
4. Brown BD, Venneri MA, Zingale A, Sergi L, Sarnow P, Kay MA. Biological basis for restriction of translation before causing mRNA decay in zebrafish. Nat Science (2012) reduct before causing mRNA decay in zebrafish. Nat Science (2012) reduct before causing mRNA decay in zebrafish. Nat Science (2012) 14:1278–83. doi:10.1038/ nm.1776
5. Dugaard I, Hansen TB. Biogenesis and function of ago-associated RNAs. Trends Genet (2017) 33:208–19. doi:10.1016/j.tig.2017.01.003
6. Bétahune J, Artus-Revel GC, Filipowicz W. Kinetic analysis reveals successive steps leading to miRNA-mediated silencing in mammalian cells. EMBO Rep (2012) 13:716–23. doi:10.1038/embor.2012.82
7. Bazzini AA, Lee MT, Giraldez AJ. Ribosome profiling shows that miR-430 reduces translation before causing mRNA decay in zebrafish. Science (2012) 336:233–7. doi:10.1126/science.1215704
8. Gu S, Jin L, Zhang F, Sarnow P, Kay MA. Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian miRNAs. Nat Struct Mol Biol (2009) 16:144–50. doi:10.1038/nsmb.1552
13. Fu X, Rivera A, Tao L, De Greest B, Zhang X. Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol Ther Nucleic Acids (2020) 6:263–9. doi:10.1016/j.mtna.2020.11.009

14. Li J-M, Kao K-C, Li-L, Yang F-M, Wu C-P, Horng Y-M, et al. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small-cell lung cancer cells. Virol J (2013) 10:241. doi:10.1186/1743-422X-10-241

15. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian Argonautes in microRNA silencing. Nucleic Acids Res (2009) 37:1412–20. doi:10.1093/nar/gkn137

16. Su H, Trombley MI, Chen J, Wang X. Essential and overlapping functions for mammalian Argonaute proteins in mediating gene silencing. Genes Dev (2009) 23:304–17. doi:10.1101/gad.1749809

17. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Mechanisms of microRNA regulation of gene expression. Nat Rev Genet (2004) 5:523–36. doi:10.1038/nrg1368

18. Valdmanis PN, Gu S, Schüermann N, Sethupathy P, Grimm D, Kay MA. Target RNA-induced repression and localization by microRNA sponges. Genes Dev (2015) 29:111–22. doi:10.1101/gad.142978.114

19. Li J-M, Kao K-C, Li-L, Yang F-M, Wu C-P, Horng Y-M, et al. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small-cell lung cancer cells. Virol J (2013) 10:241. doi:10.1186/1743-422X-10-241

20. Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC. A let-7 microRNA antagonist of the human nuclear pore complex promotes cell death. Mol Ther (2011) 19:1107–15. doi:10.1038/mt.2011.36

21. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapeutic opportunities. Hum Gene Ther Oncol (2016) 6:28075. doi:10.1038/srep28075

22. Zhao H, Dahlö M, Isaksson A, Syvänen AC, Pettersson U. The transcriptome analysis of microRNA targets in human pancreatic islets. BMC Genomics (2015) 16:907. doi:10.1186/s12864-015-1918-6

23. Huang Z, Towbin T, Chu A, Lior S, Li H, Zhou H. Distinct roles of microRNA-130a and microRNA-130b in the regulation of colorectal cancer cell invasion. Sci Rep (2016) 6:38674. doi:10.1038/srep38674

24. Kertesz M, Iovino N, Unnerstall U, Segal E. The role of site accessibility in microRNA regulation. Genes Dev (2007) 21:3536–40. doi:10.1101/gad.1613909

25. Kortes M, Lounamaa L, Tarkkanen M, Vihinen M, Gyllensten UB, Vapaatalo H. The tissue specificity of human microRNAs is determined by specific binding sites in the 3’ UTR of target mRNAs. PLoS Genet (2007) 3:1303–12. doi:10.1371/journal.pgen.0030083

26. Kamrud KI, Coffield VM, Owens G, Goodman C, Alterson K, Custer M, et al. MicroRNA-125 regulates oncolytic simplex viruses: an emerging tool for cancer treatment. Mol Ther (2011) 19:1107–15. doi:10.1038/mt.2011.36

27. Baertsch MA, Leber MF, Bossow S, Singh M, Engeland CE, Albert J, et al. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Ther (2014) 21:373–80. doi:10.1038/cgt.2014.40

28. Bofill-De Ros X, Gironella M, Fillat C. miR-148a- and miR-216a-regulated microRNAs in Oncolytic Viruses. Mol Ther (2015) 20:339–46. doi:10.1038/mt.2014.98

29. Geisler A, Jungmann A, Kurreck J, Poller W, Katas HA, Vetter R, et al. MicroRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther (2011) 18:199–209. doi:10.1038/gt.2010.141

30. Ruiz AJ, Hadac EM, Nace RA, Russell SJ. MicroRNA-detargeted mengovirus for oncolytic virotherapy. J Virol (2016) 90:4078–92. doi:10.1128/JVI.02810-15

31. van de Bunt M, Gautilon KJ, Parts L, Moran I, Johnson PR, Lindgren CM, et al. The microRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. PLoS One (2013) 8:e55064. doi:10.1371/journal.pone.0055064

32. Malmevik J, Petri R, Knauff P, Brattås PL, Åkerblom M, Jakobsson J. Distinct roles of microRNA-130a and microRNA-130b in the regulation of colorectal cancer cell invasion. Sci Rep (2016) 6:38674. doi:10.1038/srep38674

33. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet (2011) 12:99–110. doi:10.1038/nrg2936

34. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

35. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

36. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

37. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

38. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

39. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

40. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

41. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

42. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

43. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

44. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

45. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3

46. Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell (2003) 115:787–98. doi:10.1016/S0092-8674(03)01081-3
to influenza A viruses (subtypes pH1N1, H3N2, and H5N1). Exp Biol Med (2016) 241:409–20. doi:10.1177/1535370215611764

59. Chang ST, Thomas MG, Lana P, Green RR, Palermo RE, Katze MG. Next-generation sequencing of small RNAs from HIV-infected cells identifies phased microRNA expression patterns and candidate novel microRNAs differentially expressed upon infection. MBio (2013) 4:e0049–12. doi:10.1128/mbio.00499-12

60. Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, Reineke T, et al. MicroRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res (2011) 39:1880–93. doi:10.1093/nar/gkq1043

61. Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent protein 1 trans-activates miR-155 transcription through the NF-B pathway. Nucleic Acids Res (2008) 36:6608–19. doi:10.1093/nar/gkn309

62. Wang F-Z, Weber E, Croce C, Liu C-G, Liao X, Pellett PE. Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J Virol (2008) 82:9065–74. doi:10.1128/JVI.00961-08

63. Zhang Y, Dai J, Tang J, Zhou L, Zhou M. MicroRNA-649 promotes HSV-1 replication by directly targeting MALT1. J Med Virol (2017) 89:1069–79. doi:10.1002/jmv.24728

64. Thornburg NJ, Hayward SL, Crowe JE. Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-B. MBio (2012) 3:e0220–12. doi:10.1128/mbio.00220-12

65. Elton TS, Selemon H, Elton SM, Parinandi NL. Regulation of the MiR155 host gene in physiologic and pathological processes. Gene (2013) 532:1–12. doi:10.1016/j.gene.2012.12.009

66. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 up-regulation in malignant B-cell lymphomas. Science (2008) 321:16–21. doi:10.1126/science.1157031

67. Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RSB, et al. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Publ Gr (2010) 12:513–9. doi:10.1038/ncl.2008.104

68. Chiang K, Liu H, Rice AP. miR-132 enhances HIV-1 replication. Virology (2013) 438:1–4. doi:10.1016/j.virol.2012.12.016

69. Ru J, Sun H, Fan H, Wang C, Li Y, Liu M, et al. MiR-23a facilitates the replication of HSV-1 through the suppression of interferon regulatory factor 1. PLoS One (2014) 9:e114021. doi:10.1371/journal.pone.0114021

70. Wang X, Diao C, Yang X, Yang Z, Liu M, Li X, et al. ICP4-induced miR-101 attenuates HSV-1 replication. Sci Rep (2016) 6:23205. doi:10.1038/srep23205

71. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, et al. Randomized phase 2 trial of the oncolytic virus neloxo (reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther (2016) 24:1130–8. doi:10.1038/mt.2016.66

72. Nuovo GJ, Garofalo M, Valeri N, Roulstone VA, Volinia S, Cohn DE, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Proc Natl Acad Sci U S A (2007) 104:1604–9. doi:10.1073/pnas.0610731104

73. Chen Y, Chen J, Wang H, Shi J, Wu K, Liu S, et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog (2013) 9:e1003248. doi:10.1371/journal.ppat.1003248

74. Triboulet R, Mari B, Lin Y-L, Chable-Bessia C, Bennasser Y, Lebrigand K, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science (2007) 315:1579–82. doi:10.1126/science.1136319

75. Otsuka M, Jung Q, Georgel P, New L, Chen J, Mols J, et al. Hypersusceptibility to vesicular stomatitis virus infection in Dicer-1-deficient mice is due to impaired miR24 and miR93 expression. Immunity (2007) 27:123–34. doi:10.1016/j.immuni.2007.05.014

76. Lecellier C-H, Dunoyer P, Arak K, Lehmann-Che J, Eyquem S, Hinder C, et al. A cellular microRNA mediates antiviral defense in human cells. Science (2005) 308:557–60. doi:10.1126/science.1108784

77. Yanagawa-Matsuda A, Kitamura T, Higashino F, Yamano S, Totsuka Y, Shindoh M. EIF2 expression might be controlled by miR-214 in cells with low adenovirus productivity. Virus Res (2012) 170:85–90. doi:10.1016/j.viruses.2012.09.001

78. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science (2005) 309:1577–81. doi:10.1126/science.1113329

79. Li Z, Cui X, Li F, Li P, Ni M, Wang S, et al. Exploring the role of human miRNAs in virus-host interactions using systematic overlap analysis. Bioinformatics (2013) 29:2375–9. doi:10.1093/bioinformatics/btt391

80. Chang T-C, Yu D, Lee Y-S, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2008) 40:43–50. doi:10.1038/ng.2007.30

81. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature (2005) 435:834–8. doi:10.1038/nature03702

82. Hata A, Lieberman J. Dysregulation of microRNA biosynthesis and gene silencing in cancer. Sci Signal (2015) 8:rs3. doi:10.1126/escisignal.2005825

83. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med (2014) 6:851–64. doi:10.15252/emmm.201309899

84. Li X, Su Y, Sun B, Ji W, Peng Z, Xu Y, et al. An artificially designed interfering lncRNA expressed by oncolytic adenovirus competitively consumes oncomiRs to exert antitumor efficacy in hepatocellular carcinoma. Mol Cancer Ther (2016) 15:1436–51. doi:10.1158/1535-7163.MCT-16-0096

85. Zheng Y, Stamminger T, Hearing P. E2F/Rb family proteins mediate interferon induced repression of adenovirus immediate early transcription to promote persistent viral infection. PLoS Pathog (2016) 12:e1005415. doi:10.1371/journal.ppat.1005415

86. Gong J, Mita MM. Activated ras signaling pathways and reovirus oncogenesis: an update on the mechanism of preferential reovirus replication in cancer cells. Front Oncol (2014) 4:167. doi:10.3389/fonc.2014.00167

87. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 4:e353. doi:10.1371/journal.pmed.0040353

88. Cascallo M, Capellà G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res (2003) 63:5544–50.

89. Seymour LW, Fisher KD. Oncolytic viruses: finally delivering. Br J Cancer (2016) 114:537–61. doi:10.1038/bjc.2015.481

90. Fillat C, Jose A, Bofill-Deros X, Mato-Berciano A, Maliandi MV, Sobrevals L. Pancreatic cancer gene therapy: from molecular targets to delivery systems. Cancers (Basel) (2011) 3:368–95. doi:10.3390/cancers3010368

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Bofill-De Ros, Rovira-Rigau and Fillat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.